Novoseven, Novoseven RT Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The novoseven, novoseven RT market research report is one of a series of new reports that provides novoseven, novoseven RT market statistics, including novoseven, novoseven RT industry global market size, regional shares, competitors with an novoseven, novoseven RT market share, detailed novoseven, novoseven RT market segments, market trends, and opportunities, and any further data you may need to thrive in the novoseven, novoseven RT industry. This novoseven, novoseven RT research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to increased government and private sector healthcare investments, rising demand for specialized and personalized treatments, an increase in the prevalence of chronic and infectious disorders, and increasing research and development activities. Major trends in the forecast period include advancements in recombinant technology, technological innovations in medical devices and drug delivery, growing collaboration between pharmaceutical companies, advances in recombinant DNA technology, and advances in diagnostic techniques.

The growing prevalence of hemophilia is expected to drive the growth of the NovoSeven and NovoSeven RT market. Hemophilia is a rare genetic bleeding disorder caused by a deficiency or absence of specific clotting factors in the blood, impairing the body’s ability to form proper blood clots and leading to prolonged or spontaneous bleeding, especially after injuries or surgeries. The rise in hemophilia cases is attributed to factors such as improved diagnosis, better management, increasing life expectancy, and population growth. NovoSeven and NovoSeven RT are effective treatments for hemophilia, providing recombinant activated factor VII therapy that helps control and prevent bleeding episodes, particularly for patients with inhibitors to standard clotting factor therapies. This ensures better management of the condition. For example, in November 2023, the National Institutes of Health reported that in 2022, 10,276 people with hemophilia from 87 centers across 40 countries were enrolled, with 49% having severe hemophilia, 99% being male, and 85% having hemophilia A. Thus, the growing prevalence of hemophilia is driving market growth.

The increasing healthcare expenditure is expected to boost the growth of the NovoSeven and NovoSeven RT market. Healthcare expenditure refers to the total financial resources spent by individuals, governments, or organizations on medical goods, services, public health initiatives, and related activities to improve health. The increase in healthcare spending is due to factors such as aging populations, the rise in chronic diseases, and the growing demand for better healthcare infrastructure. NovoSeven and NovoSeven RT contribute to healthcare expenditure by providing effective treatments for severe bleeding conditions, such as hemophilia and postpartum hemorrhage. These treatments help reduce the need for costly emergency interventions, prolonged hospital stays, and additional procedures, improving the cost-efficiency of managing critical health conditions. For instance, in June 2024, Health Affairs projected that U.S. healthcare spending would grow from 17.3% of GDP in 2022 to 19.7% by 2032, with a 7.5% increase in national health expenditures expected for 2023. Therefore, the increasing healthcare expenditure will drive market growth.

A key trend in the NovoSeven and NovoSeven RT market is the focus on developing innovative therapeutic applications, such as the treatment of severe postpartum hemorrhage (PPH), to address unmet medical needs and expand treatment options. Severe postpartum hemorrhage refers to excessive bleeding after childbirth, which can pose significant risks to maternal health. In April 2022, Novo Nordisk announced that the European Medicines Agency had approved NovoSeven for the treatment of severe postpartum hemorrhage. This treatment offers a targeted approach to controlling life-threatening bleeding in postpartum patients, especially those who do not respond to conventional therapies. The approval highlights the ability of NovoSeven to rapidly enhance blood clotting, providing a crucial solution for managing severe hemorrhage where traditional uterotonics and surgical interventions may be ineffective.

The key company operating in the novoseven, novoseven RT market IS Novo Nordisk A/S.

North America was the largest region in the novoseven, novoseven RT market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in novoseven, novoseven RT report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the novoseven, novoseven RT market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Novoseven and Novoseven RT are recombinant activated factor VII (rFVIIa) medications designed to support blood clotting in individuals with specific bleeding disorders, including hemophilia A or B with inhibitors, congenital factor VII deficiency, and Glanzmann’s thrombasthenia. They are primarily utilized to manage bleeding episodes and during surgical or invasive procedures in these patients.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main indications for Novoseven and Novoseven RT include hemophilia A, hemophilia B, and other rare bleeding disorders. Hemophilia A is a genetic condition characterized by a deficiency or dysfunction of clotting factor VIII, leading to prolonged bleeding episodes. Effective management of this disorder is essential to prevent spontaneous or excessive bleeding, which can be life-threatening if left untreated. These medications are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and are used by a wide range of patients, including adults, pediatric patients, and the elderly.

The novoseven, novoseven RT market consists of sales of recombinant factor viii, activated prothrombin complex concentrates, and cryoprecipitate. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.